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Abstract
Background: Cardiotoxicity from anticancer therapy affects heart function and structure. Cardiotoxicity can also
lead to accelerated development of chronic diseases, especially in the presence of risk factors.
Methods: This study aimed to develop and pilot a combined cardiovascular disease and cardiotoxicity risk
assessment questionnaire to quantify the potential extent of risk factors in breast cancer patients prior to treatment.
The questionnaire underwent content and face validity evaluation by an expert panel followed by pilot testing in a
sample of breast cancer patients (n = 36). Questionnaires were self-administered while attending chemotherapy
clinic, in the presence of a research assistant.
Results: Mean age of participants was 54.8 years (range 36–72 years). Participants reported CVD risk factors including
diabetes 2.8%, hypertension 19.8%, hypercholesterolaemia 11% and sleep apnoea 5%. Lifestyle risk factors, included not
eating the recommended serves of vegetables (100%) or fruit (78%) per day; smoking (13%) and regularly consuming
alcohol (75%). Twenty five percent reported being physically inactive, 61%, overweight or obese, 24%, little or no social
support and 30% recorded high to very high psychological distress. Participants were highly (75%) reluctant to
undertake lifestyle changes; i.e. changing alcohol consumption; dietary habits; good emotional/mental health
strategies; improving physical activity; quitting smoking; learning about heart-health and weight loss.
Conclusion: This study is an important step towards prevention and management of treatment-associated
cardiotoxicity after breast cancer diagnosis. We recommend that our questionnaire is providing important data that
should be included in cancer registries so that researchers can establish the relationship between CVD risk profile and
cardiotoxicity outcomes and that this study revealed important teaching opportunities that could be used to examine
the impact on health literacy and help patients better understand the consequences of cancer treatment.
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Background
Advances in screening, early detection and treatment of
cancer have led to improved survival of patients with
cancer, but have also increased morbidity and mortality
due to treatment side effects [1]. Cardiotoxicity from
anticancer therapy is a direct effect of cancer treatment
on heart function and structure and one of the most
common toxicities of cancer treatment, leading to accel-
erated development of cardiovascular disease (CVD),
especially in the presence of traditional cardiovascular
risk factors [2]. Cardiotoxicity is particularly common in
cancers treated with anthracyclines and radiation ther-
apy, of which breast cancer is the most common [2].
Approximately 14,200 cases of breast cancer are
diagnosed annually in Australia, with five and ten-year
survival rates of 89% and 83% respectively [3]. A leading
cause of mortality, breast cancer is primarily a disease of
older women [4] and as the population ages, more
women are likely to be diagnosed, and live longer, after
treatment. Although breast cancer therapy is increas-
ingly effective in improving tumour-free survival, this
may not always translate into better overall survival
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because of treatment-related side effects, including car-
diotoxicity. Indeed, in older women diagnosed with
breast cancer (who are the majority of those diagnosed),
mortality from heart failure now exceeds cancer-specific
mortality after ten years [5]. Agents most frequently as-
sociated with cardiotoxicity include anthracyclines (1–
26% of patients), high-dose cyclophosphamides (7–28%),
trastuzumab (2–28%) and tyrosine kinase inhibitors
(0.05–11%), all of which are frequently used in the treat-
ment of breast cancer [5, 6]. Chest irradiation and many
drugs used in breast cancer (e.g. anthracyclines) are im-
plicated in this toxicity [6, 7]. Compounding this prob-
lem, 90% of Australians have at least one cardiac risk
factor increasing their predisposition to toxicity. They
have a seven-fold higher risk of heart failure death and a
15-fold higher risk of heart failure than the general
population [5, 8]. The challenge is to tailor treatment to
the molecular nature of the disease while simultaneously
modifying its cardiac effects [6].
Cardiac clinicians routinely assess socio-demographic
factors (e.g. level of education and access to health ser-
vices) and manage psychosocial factors (e.g. depression)
and lifestyle factors (e.g. diet, exercise and the patient’s
ability to modify lifestyle) to reduce patients’ risk of car-
diac disease. The authors, supported by recent literature,
propose that these could be as important to consider as
chemotherapy agent and dose in the assessment and
management of cancer [5, 9].
To realise the potential of breast cancer treatments, can-
cer clinicians need assessment strategies that enable them
to accurately identify treatment-related and pre-existing
cardiac risks and to modify their combined potential to in-
duce heart disease in breast cancer patients [10]. Given that
a normal left ventricular ejection fraction at baseline cannot
exclude the possibility of subsequent cardiotoxicity, serial
cardiac imaging to assess left ventricular function is usually
performed to identify patients who develop cardiotoxi-
city; however, outcomes are generally poor once a pa-
tient develops clinical heart failure [10].
The most recent European Society of Cardiology
(ESC) position paper on cancer treatments and cardio-
vascular toxicity suggests that identifying high-risk
patients prior to the administration of cancer therapy
may allow treatment modifications to decrease the risk
of subsequently developing cardiotoxicity [2]. However,
this requires a better understanding of the predisposing
factors for the development of CVD related to cancer
treatment. We propose that a breast cancer-specific car-
diotoxicity risk assessment, which stratifies patients to
an individually tailored risk management plan, is
warranted. Previous cardiotoxicity assessment tools have
focused only on the factors with established causality
(e.g. age, previous CVD, and chemotherapy or radiother-
apy regime) [11–13]; however, currently there is no
questionnaire that enables such a comprehensive CVD
risk profile assessment specific to breast, or any other,
cancer care [14].
Methods
Aim
The aim of this study was to produce a standardised,
comprehensive approach to assessing CVD and cardio-
toxicity risk before breast cancer treatment.
There were two objectives:
1. To develop and pilot test the risk assessment
questionnaire; and
2. To obtain preliminary data on the extent and nature
of modifiable and non-modifiable cardiovascular risk
factors for cardiotoxicity in breast cancer patients.
Design
This study was undertaken in two parts. Initially content
development and face validity testing of a questionnaire
by an expert panel to assess cardiotoxicity risk, based on
the ESC position paper for cardiotoxicity baseline risk
factors (Table 1). Following this, the questionnaire was
piloted in a sample of breast cancer patients from two
oncology clinics in Australia.
Content development and face validity
A small working group of the expert panel members col-
lated a battery of demographic, clinical and validated
cardiovascular risk factor assessment tools (Table 2) to
form the first draft of the questionnaire. The expert
panel (n = 14) comprised representatives from the fields
of medical oncology, cardiology, radiation oncology,
dietetics, cancer nursing, psycho-oncology, pharmacy,
exercise physiology, and two consumer representatives.
All members volunteered to provide feedback on the
draft questionnaire electronically in two rounds.
In Round 1, panel members were asked to provide un-
structured feedback on all aspects of the preliminary
questionnaire. Their qualitative responses were synthe-
sised, reduced and categorised to further modify the
questionnaire. The modified questionnaire underwent
two further electronic consensus rounds. These rounds
focussed on ensuring that all the important items were
incorporated; that there was no overlap or ambiguity of
items; that items were scored appropriately; and that the
questionnaire was relevant to end-users. In addition, the
expert panel members were asked to complete a content
validity index (CVI) on each question or section (e.g.
pre-existing tool). The CVI was a four-point Likert scale
that assessed the clarity of each item used, wherein
1 = very unclear, 2 = unclear, 3 = clear, 4 = very clear.
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Pilot testing questionnaire
Setting
The questionnaire was pilot tested for feasibility and ac-
ceptability by thirty-six patients from two Australian
public facility oncology clinics, one in South Australia
and the other in Queensland, between October 2015 and
March 2016. As this was a pilot study using a battery of
validated instruments, a power calculation was not
applicable. The sample size of thirty-six was based on
feasibility, time and funding. It is intended that
outcomes from this study will be used to generate sam-
ple size calculations for future large cohort testing of the
questionnaire.
Consumer involvement
This team of investigators recognises that consumers’
experience of breast cancer, their knowledge of the moti-
vations and capacities of consumers to engage with re-
search, coupled with their awareness of consumers’
needs, were integral to the success of this initiative. We
Table 2 Summary of published instruments used to evaluate cardiovascular risk factors
Data item Measurement Reference Question number
Household income categories Australian Bureau of Statistics Cat 6523.0 Household Income and Wealth,
Australia, 2013–141 [35]
3
Nutrition Fruit and Vegetable Serves [32] 5
Alcohol consumption Australian guidelines to reduce health risks from drinking alcohol [27] 17
Physical activity The Godin-Shephard leisure-time physical activity questionnaire [21] 18–21
Emotional health Kessler Psychological Distress Scale (K10) [18] 23
MMOS_SS [19]
Cardiac Health York Cardiac Beliefs Questionnaire [25] 24
Sleep Simplified model of screening questionnaire and home monitoring
for obstructive sleep apnoea in primary care [33]
37
Body Mass Index and Waist circumference National Health and Medical Research Council (2013) Clinical practice
guidelines for the management of overweight and obesity in adults,
adolescents and children in Australia [34]
12
Summary of questionnaires used to evaluate risk factors
Table 1 Baseline risk factors for Cardiotoxicity (ESC Guidelines)
Current myocardial disease Demographic and other CVD risk factors
• Heart failure (with either preserved or reduced ejection fraction) Age (paediatric population < 18 years; >50 years for trastuzumab;
>65 years for anthracyclines)
• Asymptomatic LV dysfunction (LVEF <50% or high natriuretic peptidea) Family history of premature CV disease (<50 years)
• Evidence of CAD (previous myocardial infarction, angina, PCI or
CABG, myocardial ischaemia)
Arterial hypertension
Diabetes mellitus
Hypercholesterolaemia• Moderate and severe VHD with LVH or LV impairment
• Hypertensive heart disease with LV hypertrophy
• Hypertrophic cardiomyopathy
• Dilated cardiomyopathy
• Restrictive cardiomyopathy
• Cardiac sarcoidosis with myocardial involvement
• Significant cardiac arrhythmias (e.g.AF, ventricular tachyarrhythmias)
Previous cardiotoxic cancer treatment Lifestyle risk factors
• Prior anthracycline use • Smoking
• Prior radiotherapy to chest or mediastinum • High alcohol intake
• Obesity
• Sedentary habit
Summary of baseline risk factors for cardiotoxicity
AF atrial fibrillation, CABG coronary artery bypass graft, CAD coronary artery disease, CV cardiovascular, LV eft ventricule, LVEF left ventricular ejection fraction, LVH
left ventricular hypertrophy, VHD valvular heart disease. B-type natriuretic peptide .100 pg/ml or N-terminal pro-B-type natriuretic peptide .400 pg/ml with no
alternative cause
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consulted the Breast Cancer Network of Australia
(BCNA) and the Australian National Heart Foundation
in developing this project. We did so because the con-
sumer representatives of these organisations are sup-
ported and trained to engage meaningfully in the
research context and to advocate for consumers with
different experiences to their own. Consumers and pol-
icy advisors from both organisations kindly contributed
valuable advice about the content, relevance and feasibil-
ity of this study, and the BCNA consumer representa-
tives agreed to be named as co-investigators.
Participants
Inclusion criteria for participants were: a new diagnosis
of breast cancer; referral for chemotherapy and/or radi-
ation therapy, up to third chemotherapy cycle; and able
to provide informed consent. Exclusion criteria were: be-
yond third chemotherapy cycle; and unable or unwilling
to give consent, or participate.
Recruitment and consent
Eligible patients were selected by the clinical oncologist
at each site and introduced to the research assistants
(RAs). Once patients had been identified, they were
approached during their waiting period on, or before,
the third session of chemotherapy/radiotherapy treat-
ment and invited to participate in a research survey
about cardiotoxicity. Patients were given the participant
information sheet and consent form to read, either at
that time, or later in their own time. Once consent was
received, the participant was given the questionnaire to
complete while they waited for chemotherapy. An RA
from the team was present to answer any questions that
may have arisen, and to collect the data once the re-
spondent had completed the questionnaire.
Data sources
Data were sourced from the medical records of partici-
pants for demographics and clinical information (such
as diagnosis and chemotherapy regime), as well as self-
reported data from the tools within the questionnaire.
Variables
Cardiac risk factors
As per National Heart Foundation guidelines [15], items
collected included smoking, high blood cholesterol and
high blood pressure; history of cardiovascular disease,
diabetes, age ≥ 65 years, ethnicity, family history of car-
diac disease and body mass index (BMI) [16]. Other
non-modifiable risk factors included education level,
postcode, income level, and private health insurance.
These questions were taken directly from the Australian
Bureau of Statistics (ABS) census [17]. All of these risk
factors can be compared to the prevalence within the
total Australian population.
Cancer and cancer treatment-related factors
Items included were: cumulative anthracycline dose
≥550 mg—particularly bolus administration—alone or in
conjunction with infusional 5-fluorouracil, capecitabine, or
taxanes; high-dose cyclophosphamide; aromatase inhibitor or
tamoxifen therapy; mTOR inhibition; HER-2 blocking agents,
e.g. trastuzumab; anti-angiogenic agents, e.g. bevacizumab;
chest irradiation; and co-morbidity of blood cancer [2].
Psychosocial factors
Psychosocial factors were measured using the Kessler
Psychological Distress Scale (K10) [18] and the eight-
item modified Medical Outcomes Study Social Support
Survey (MMOS-SS) [19]. Cardiac health behaviour, abil-
ity, willingness, knowledge and attitudes (ordinal and
Likert-scale data) and standard items from the ABS
Australian Health Survey (AHS) [20] elicited patients’
modifiable health practices, such as food choices, smok-
ing, and alcohol consumption. Physical activity was mea-
sured with the Godin Leisure TimE Questionnaire
(GLTEQ) [21] and exercise practices were asked as per
the current unhealthy CVD risk factor and lifestyle pro-
file of the general Australian population [22, 23]. These
AHS items enabled comparison with national rates for
these activities. Fruit and vegetable consumption was
measured using two items from the South Australian
Monitoring and Surveillance System (SAMSS) [24]. To
gain insight into the participant’s health literacy, know-
ledge and beliefs around heart disease and its treatment,
we included the York Cardiac Beliefs Questionnaire [25].
Patient content validation
Participants were asked four additional questions to as-
certain their opinion of the questionnaire items: 1)
whether the items were easy to understand; 2) whether
the items were relevant; 3) whether the format was ac-
ceptable; and 4) whether the time taken to complete the
assessment was acceptable.
Statistical analysis
Data were manually entered from the questionnaires
into Microsoft Excel and a 10% quality data assessment
was completed for accuracy. Missing data were exam-
ined for extent, pattern, and randomly or systematically
missing. Depending on the potential source of bias
entailed in the missing data, an appropriate method (e.g.
item deletion or data imputation) was then used. All
data were then imported into Statistical Package for the
Social Sciences (SPSS) for Windows, Version 20.0 [26],
for analysis.
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Participant characteristics and clinical data are pre-
sented as frequency and summary descriptive statistics.
Continuous variables have been reported as means and
standard deviations for normally distributed data. Pro-
portions summarise categorical variables. Comparability
of treatments received as per recruitment pathways have
been evaluated for participants’ demographic and med-
ical characteristics using cross-tabulations.
Results
Questionnaire content development and validity testing
The expert panel assessed the questionnaire in terms of
item relevance using the Likert scales for each section
with a mean CVI per item of at least three needed to be
accepted. If not, items were modified through further
expert panel consultation or deleted, after which consen-
sus was obtained on the final version of the question-
naire. The final questionnaire contained 19 pages and
355 items or variables (151 from clinical notes and 204
self-reported). These covered demographics, clinical his-
tory, cancer treatment, and validated tools to measure
current cardiovascular risk factors, cardiac disease and
health literacy.
Pilot test
The pilot study aimed to recruit twenty participants
from each site for a total of forty participants. Final re-
cruitment was thirty-six on completion of the recruit-
ment period.
Characteristics of participants
A summary of the characteristics, cancer diagnoses and
treatment, and cardiovascular risk factors are presented
in Table 3 and where possible have been compared to
Australian norms. The mean age of participants was
54.8 years compared to the national average for women,
which was 39.4 years. Within the group, 5.6% identified
as being of Aboriginal and/or Torres Strait Islander des-
cent compared to the national reported 2.5%. One pa-
tient had a family history of myocardial infarction.
Participants reported CVD risk factors including dia-
betes 2.8%, hypertension 19.8%, hypercholesterolemia
11%, and sleep apnoea 5%.
The lifestyle CVD risk factor questions revealed that
no participants were eating the recommended five serves
of vegetables per day and 22% ate the recommended two
serves of fruits per day [27]. Thirteen percent reported
being current smokers and 75% regular consumers of al-
cohol. Additionally, 25% reported being physically in-
active, 24% had little to no social support and 30%
recorded high to very high psychological distress. The
participants reported sleeping less than the national
average (6.7 h compared to 7.3 h per night), and 61 % of
participants were overweight (BMI ≥ 25 kg/m2).
Cardiotoxicity risk factors
Details of known risk factors for cardiotoxicity from can-
cer treatment are detailed in Table 1 [2]. In this small
group of breast cancer patients there was a high poten-
tial for cardiotoxicity with 76% of the participants being
over fifty years of age, 30% having pre-existing CVD or
other chronic diseases, and only one third of participants
having had a prior electrocardiogram or a prior echocar-
diogram (Table 4) [2].
Knowledge of heart disease
Knowledge and beliefs of heart disease are presented in
Table 5. There was considerable misconception (25.5%)
or no knowledge (6.9%) about heart disease within this
group.
Willingness to modify risk factors and make lifestyle
changes
One of the final questions in the questionnaire asked if
participants would be interested in receiving further in-
formation or support about risk factor and/or lifestyle
modification (see Table 6). Generally there was a high
level of unwillingness to undertake lifestyle changes with
88% stating they were not prepared to modify alcohol
consumption; 44% unwilling to modify dietary habits;
72% not interested in receiving good emotional/mental
health strategies; 61% not willing to improve physical ac-
tivity; 68% of smokers unwilling to receive information
about quitting; and 50–78% not interested in learning
more about heart health or losing weight.
Completion of questionnaire
The average time taken for participants to complete the
questionnaire was 25 min. Times ranged from 20 to
45 min. Participants reported both positive and negative
views. Two recurring themes were confusion about why
we were talking about heart issues in the cancer clinic,
and the time required to complete the questionnaire.
Other feedback and comments
In the section where participants were asked to give
feedback on the questionnaire, 75% of participants took
the opportunity to give feedback. Positive comments in-
cluded saying that the questions were well worded or
suggesting relevant question improvements. Negative
comments related to why we were asking about income
and why we were asking questions about the heart in a
chemotherapy clinic.
Discussion
Previous cardiotoxicity assessment tools have focused
only on factors with established causality e.g. age, previ-
ous CVD, and chemotherapy or radiotherapy regime
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[11–13]. The aim of this study was to produce a standar-
dised, comprehensive approach to assessing the risk of
cardiotoxicity, which included assessment and measure-
ment of CVD risk and lifestyle factors that may indicate
undiagnosed CVD prior to cancer treatment. From a
nursing point of view, as many risk factors for cancer
and CVD are the same, this questionnaire could create a
‘teaching moment’ and an opportunity to introduce risk
management and lifestyle education as part of cancer
treatment [28, 29]. Future studies exploring the role of
patient education as a strategy to change behaviour and
increase engagement in care are warranted.
During questionnaire development, there were two
important findings. Firstly, the questionnaire was large
(19 pages with 355 items) and took an average of
twenty-five minutes to complete. It is recommended that
further work be carried out to shorten the questionnaire
before this data collection tool is used again. There was
a large variation in the waiting times within the two pre-
chemotherapy clinics and some participants became dis-
tressed at needing to complete such a large document
while waiting to be called to chemotherapy. Others
needed to take the questionnaire home to complete. In
this case, they were supplied with a reply paid envelope
to return to us by mail. An alternative approach may be
to administer questionnaires for cardiotoxicity risk as-
sessment while waiting for routine echocardiography
prior to cancer treatment; however, only one third of the
patients in our study reported having an echocardiogram
prior to chemotherapy. Whilst this may have been
under-reported, this would still be unlikely to result in a
comprehensive capture. Given that cardiac imaging is
Table 3 Summary of Cancer and Cardiovascular Risk Factors
Risk Factors Participants n = 36 Australian Population
n (%) %
Mean age years (Female) Range (36–72 years) 54.8 39.4
Sex (Female) 36 (100) 50.3
Indigenous status 2 (5.6) 3.1
Usual residence -Metropolitan area 27 (75) 68.5
Family History Type 2 Diabetes 0 (0) –
Family History Hypertension 0 (0) –
Family History Hypercholesterolaemia 1 (2.8) –
Family History Myocardial Infarction 1 (2.8) –
Patient History Type 2 Diabetes 1 (2.8) 4.6
Patient History Hypertension 7 (19.5) 21.5
Patient History Hypercholesterolaemia 4 (11.1) 32.3
Patient History Previous History Myocardial Infarction 0 (0) 3.4
Eats recommended 5 vegetable serves per day 0 (0) 8
Eats recommended 2 fruit serves per day 22 (62.9) 48
Current smoker 5 (13.9) 16
Alcohol intake (at least once a week) 8 (22.2) 37.7
Moderately active or active physically 27 (75) 44
Little or no social support 8.7 (24.2) –
High to very high K10 score (22–50) 8 (29.6) 10.8
Earnings below the total gross mean Australian annual household income 26 (72.2) 80
Earnings above the total gross mean Australian annual household income 3 (8.3) 20
Household income: Prefer not to answer 7 (19.4) 0
Sleep
Mean hours of sleep per night 6.7 (NA) 7.3
Snoring (regular) 13 (36.1) –
Sleep apnoea diagnosis 2 (5.7) 4.0
Body Mass Index (BMI >25 kg/m2 Overweight) 22 (61.1) 63
Waist circumference ≥ 80 cm (Heart Foundation recommendation for women) 4 (100) 79.4
Demographic and clinical characteristics of participants
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performed by different service providers, this further
complicates the data collection.
Secondly, many participants asked the research team
why they were being asked about their heart health in
the breast cancer chemotherapy clinic. This was a posi-
tive finding for the research as it indicated to our team
that we had created a teaching opportunity.
In the pilot testing, as expected, we found an older
group of women than the mean national age (54.8 years
Table 4 Summary of participant cardiotoxicity risk factors
Characteristics (n = 36) Participants n (%)
Age > 50 years 27 (76)
Cancer type
Breast 22 (61.2)
Breast left 2 (5.6)
Carcinoma of breast (elective (L)
mastectomy 4/8/15)
1 (2.8)
Lower-inner quadrant of breast 1 (2.8)
Malignant breast cancer 1 (2.8)
Malignant neoplasm of breast 3 (8.3)
Malignant neoplasm of upper-outer
quadrant of breast
1 (2.8)
Metastatic HER-2 pos breast cancer 1 (2.8)
Palpable cancer right breast 1 (2.8)
Missing 3 (8.3)
Chemotherapy
Mean number of chemotherapy cycles 4.9 (Median 3) Range (1–16)
Agent class Mean Dose (mg) n (%)
Alkylating agents
Carboplatin 658 5 (13.8%)
Cyclophosphamide 1073 20 (56%)
Anthracyclines
Doxorubicin 110 11 (30%)
Antimetabolites
Fluorouracil 996 6 (17%)
Mitotic Inhibitors
Docetaxel 158 15 (42%)
Paclitaxel 156 20 (56%)
Monoclonal Antibody
Denosumab 120 1 (2%)
Trastuzumab 493 13 (36%)
Baseline Cardiac Assessment
Echocardiography 14 (38.9)
Left Ventricular Ejection Fraction <45% 0 (0)
Angiography 1 (2.8)
Electrocardiogram 11 (30.6)
Summary of cardiotoxicity risk factors
Table 5 York Angina Knowledge and Beliefs
Cardiac Health (Respondents n = 36) Incorrect belief
n (%)
No Knowledge
n (%)
One of the main causes of heart
disease is stress
23 (63.9) 2 (5.6)
Heart problems will definitely shorten
your life whatever age you are
21 (58.3) 2 (5.6)
Angina is a kind of small heart attack 19 (54.3) 4 (11.1)
Once you have had one heart attack
you are bound to have another one
18 (50) 3 (8.3)
A heart attack makes a weak area in
the heart wall that can easily rupture
16 (44) 8 (22.2)
People who have heart problem
should always avoid stress
13 (36.1) 3 (8.3)
It’s okay to disagree with people
with heart problems
12 (33.3) 2 (5.6)
It is dangerous for people who have
heart problems to argue
12 (33.3) 2 (5.6)
People with heart disease should
take life easy
11 (30.6) 3 (8.3)
People develop heart disease because
of worry in their life
10 (27.8) 2 (5.6)
Any sort of excitement could be
bad if you have heart problems
9 (25.0) 3 (8.3)
It’s a good idea to check to see how
you feel before doing something
9 (25.0) 3 (8.3)
Heart problems are a sign that you
have a worn out heart
9 (25.0) 4 (11.1)
It is important to avoid anything that
might bring on angina or chest pain
9 (25.0) 2 (5.6)
Rest is the best medicine for heart
problems
9 (25.0) 2 (5.6)
People who have heart problems
should never get excited or upset
8 (22.2) 2 (5.6)
Your heart is like a battery, the more
you do, the faster it runs down
7 (19.4) 3 (8.3)
People with heart problems should
live life to the full
5 (13.9) 3 (8.3)
There’s not much you can do about
heart problems
4 (11.1) 2 (5.6)
Heart problems are often caused by
peoples’ lifestyle
4 (11.1) 6 (16.7)
Doing exercise can strengthen the
heart muscle
2 (5.6) 3 (8.3)
It is important for people with heart
problems to carry on doing enjoyable
things
2 (5.6) 2 (5.6)
You can reduce your risk of more
heart problems
1 (2.8) 1 (2.8)
Changing your lifestyle can reduce
your risk of more heart problems
0 (0) 2 (5.6)
Mean Incorrect Beliefs and No knowledge (%)
25.5% 6.9%
Heart health knowledge and beliefs
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compared to 39.4 years national average). According to
the ESC guidelines, age is a risk factor for cardiotoxicity
particularly for those fifty years and over. The diagnoses
of the participants indicated that they would be receiving
potentially cardiotoxic chemotherapy and each patient’s
regimen comprised individualised composites and doses
of the cytotoxic agents. There was evidence of pre-
existing risk factors for CVD in 30% of participants and
61% were overweight or obese reflecting the current
CVD risk factor profile of all Australians [22, 23]. Partic-
ipants reported a strong unwillingness to undertake life-
style changes. We acknowledge that some of the
unwillingness would have been related to a wish to deal
with the cancer issues and possibly an inability to do
things like physical activity due to the acute effects of
treatment (e.g. nausea and lethargy). However, our re-
sults would indicate an opportunity for cardio-oncology
educational interventions similar to models that are be-
ing researched internationally [28, 30, 31].
Relevance to breast cancer patients
The outcomes of this study are relevant to all cancer pa-
tients and cancer survivors who have received potential
cardiotoxic cancer treatment and the authors stress the
importance of a cardio-oncology co-management of pa-
tients with an increased burden of risk factors. Austra-
lian health services do not currently undertake
standardised, comprehensive cardiac risk assessments in
breast cancer patients, nor do they provide structured
health promotion programs to support breast cancer
consumers to minimise lifestyle-related cardiac risk dur-
ing and after treatment, despite the public and personal
health benefits that these would provide. A range of sur-
vivorship programs have been implemented in recent
years in recognition of the chronic nature of cancer;
however, most targeted specific symptoms and were not
grounded in sound chronic disease self-management
principles and the benefits, not only for heart health but
effects on cancer recurrence [2]. They are also not
tailored to the distinct needs of breast cancer survivors,
such as difficulties engaging in exercise after breast re-
construction and body image issues [9]. As the field of
cardio-oncology grows and develops, it is hoped that the
collaboration between cancer and cardiology clinicians
will facilitate a comprehensive and seamless approach to
care for cancer patients at risk of heart disease.
Implications for translation to practice and further research
This pilot study provides preliminary data for an effective-
ness trial to measure the impact of CVD profiling and car-
diotoxicity risk assessment, to provide an appropriate
clinical pathway to manage patients safely through their
cancer treatment. The project team will utilise a ‘bottom
up’ approach to drive the translation of this approach into
practice, working directly with our established network of
consumers, clinicians and key cancer organisations to en-
sure their engagement. We will demonstrate the personal,
clinical and cost-effectiveness benefits of our approach,
with the goal being to increase both consumer and clin-
ician awareness and understanding of cardiotoxicity.
Limitations
This study was a pilot and generalisability is limited. The
results of the study have provided important lessons
about the size, timing, design, location and mode of de-
livery of the data collection. This was not a random sam-
ple of participants and there may have been bias in
sampling as oncologists may have chosen patients who
were at a higher literacy level, or who were coping better
with chemotherapy, than other potential participants.
This may have led to selection bias.
Future research
Valuable lessons will be implemented in the next phase of
our research. The opportunity to expand on the teaching
opportunities revealed during this pilot study could be used
to examine impact on health literacy and help patients bet-
ter understand the consequences of cancer treatment.
Conclusion
This study is an important first step towards evidence-
based and personalised assessment, prevention and man-
agement of treatment-associated cardiotoxicity after
breast cancer. Important teaching opportunities revealed
during this pilot study could be used to examine the
impact on health literacy and help patients better under-
stand the consequences of cancer treatment. We recom-
mend that our questionnaire is providing important data
that should be included in cancer registries so that re-
searchers can establish the relationship between CVD
risk profile and cardiotoxicity outcomes.
Table 6 Willingness to modify risk factors or make lifestyle
changes
Cardiovascular and Cancer Risk Factors aUnwilling to make lifestyle
changes n (%)
Alcohol consumption 16 (88.9)
Dietary habits 16 (44.4)
Good emotional/mental health strategies 26 (72.2)
Exercising/physical activity 22 (61.1)
Quit smoking (smokers) 4 (66.7)
Understanding heart health 28 (77.8)
Weight loss or gain 18 (50)
Willingness to make lifestyle changes
aData only from participants who had the nominated risk factors
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